RxDoctor Payments DataLook up a doctor →

Benjamin George, MD

Medical Oncology · Colby, KSNPI 1811968225

Payments from drug & device makers

$1,093,611in general payments, 2019–2025

Across 366 payments — averaging $2988.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Karyopharm Therapeutics Inc.$462K
  • E.r. Squibb & Sons, L.L.C.$380K
  • Seagen Inc.$149K
  • Epizyme, Inc.$31K
  • Napo Pharmaceuticals Inc$23K
  • AstraZeneca$14K
  • plus $35K from 34 others

What the payments were for

  • Consulting fees$60,97614%
  • Speaking & faculty fees$325,72475%
  • Travel & lodging$40,1519%
  • Food & beverage$5,5371%
  • Education$1510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,093,611 in reported general payments places this provider in the 70th percentile of 25 medical oncology providers in Kansas.

See all medical oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$78,455
Medicare patients
266
Services billed
792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide29$365,089
RevlimidLenalidomide17$263,528
ImbruvicaIbrutinib16$263,192
VerzenioAbemaciclib11$162,176
Abiraterone Acetate21$29,287
Everolimus12$26,192
EliquisApixaban12$6,860
Enoxaparin Sodium12$3,494
Anastrozole63$1,365
Dexamethasone69$924
Prochlorperazine Maleate54$667
Acyclovir49$621
Letrozole39$554
Ondansetron Hcl43$506
Tamoxifen Citrate24$431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$5,566$263,52817 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$139$263,19216 claims
Lilly USA, LLCVerzenio$26$162,17611 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$9,435$29,28721 claims
PfizerEliquis$116$6,86012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 25 medical oncology providers in Kansas.

Other medical oncology in Colby

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →